Update on B-cell targeted therapies for systemic lupus erythematosus.

about

Decrease of Functional Activated T and B Cells and Treatment of Glomerulonephitis in Lupus-Prone Mice Using a Natural Flavonoid Astilbin DNA-reactive B cells in lupus.Treat-to-target in systemic lupus erythematosus: are we there yet?

P2860

Q35389559-B3DC6D81-1EBB-48F1-ACA0-71C7A83F8CDE Q38922669-D3381E31-BBC6-403E-A60D-C4DD79DA9E36 Q47846085-22A0AC6B-352B-440B-B91C-FC23F48ECCAB

P2860

Update on B-cell targeted therapies for systemic lupus erythematosus.

Item

http://www.wikidata.org/entity/Q38192656

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Update on B-cell targeted therapies for systemic lupus erythematosus.

@en

type

Item

label

Update on B-cell targeted therapies for systemic lupus erythematosus.

@en

prefLabel

Update on B-cell targeted therapies for systemic lupus erythematosus.

@en

P1476

Update on B-cell targeted therapies for systemic lupus erythematosus.

@en

P2093

Chi Chiu Mok

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis of systemic lupus erythematosus

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Belimumab for systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.

P304

773-788

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2014.895810

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24588110

http://www.w3.org/2001/XMLSchema#string

Update on B-cell targeted therapies for systemic lupus erythematosus.

about

P2860

P2860

Update on B-cell targeted therapies for systemic lupus erythematosus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698